Tokai initiates trial of galeterone in men with AR-V7-positive mCRPC

According to information released earlier today by Tokai Pharmaceuticals, the company has started to enroll patients with AR-V7-positive, metastatic, castration-resistant prostate cancer (mCRPC) into a randomized Phase III clinical trial of treatment with galeterone. … READ MORE …

NICE rejects coverage of enzalutamide in men with chemo-naive mCRPC

According to a report on Yahoo!News, the National Institute for Care and Health Excellence (NICE) in the UK has issued draft guidance suggesting that enzalutamide is not sufficiently cost-effective for use in the treatment of men with chemotherapy-naive, metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …

NICE recommends coverage of radium-223, but …

According to a recent report in Pharma Times, the National Institute for Health and Care Excellence (NICE) in the UK is recommending coverage of treatment with radium-223 dichoride (Xofigo) but has changed its mind about coverage of degarelix (Firmagon). … READ MORE …

International group creates better gene map for men with mCRPC

A new article in the journal Cell is being said to “clarify the genetic backgrounds of men with metastatic, castration-resistant prostate cancer” (mCRPC). It also suggests that most cases of prostate cancer are “sensitive to drugs already available or under development.” … READ MORE …

PSMA ADC in treatment of mCRPC post-chemo and post-abiraterone and/or enzalutamide

Data from an open-label Phase II trial of PSMA ADC — a fully human IgG1 antibody conjugated to monomethyl auristatin E (MMAE) — suggests that this agent has activity in treatment of metastatic, castration-resistant prostate cancer (mCRPC) patients who have already progressed on abiraterone acetate and/or enzalutamide. … READ MORE …

Current and “next generation” treatments for mCRPC: a new review

For those actually dealing with metastatic, castration-resistant prostate cancer (mCRPC) or who think they may be faced with dealing with this in the near future, there is a new review of current and future treatments for mCRPC available on the Medscape Oncology web site. … READ MORE …

Enzalutamide shows positive outcome in TERRAIN trial

A media release issued today by Medivation and Astellas Pharma, based on data presented at the European Association of Urology meeting in Madrid, Spain, states that enzalutamide appears to extend progression-free survival (PFS) better than bicalutamide in the randomized, Phase II TERRAIN trial. … READ MORE …

Follow

Get every new post delivered to your Inbox.

Join 1,342 other followers